Wednesday January 22, 2020

Here’s Why Diabetes Can Be an Independent Risk Factor for Heart Failure

The study shows that diabetes is an independent risk factor for the development of heart failure in the community dwelling population

0
//
Diabetes
The study shows that diabetes is an independent risk factor for the development of heart failure in the community dwelling population. Pixabay

Heart problems are a common development for people with diabetes and now researchers have found that diabetes is an independent risk factor for the development of heart failure in the community dwelling population.

According to health expert in India, if poorly controlled, diabetes leads to cardiomyopathy resulting in progressive deterioration of pumping capacity of heart.

“Diabetes is also a major risk factor for atherosclerosis and this eventually leads to blockage of coronary arteries. This leads to heart attack or myocardial infarction,” Satish Koul, HOD and Director Internal Medicine, Narayana Superspeciality Hospital, Gurugram, told IANS.

“Due to myocardial infarction, the heart muscle becomes weak and eventually heart fails as a pump leading to congestive heart failure,” Koul added.

According to the current study, published in the journal Mayo Clinic Proceedings, researchers evaluated the long-term impact of diabetes on the development of heart failure, both with preserved ejection fraction – a measurement of the percentage of blood leaving the heart with each contraction – and reduced ejection fraction.

They also looked at mortality in a community population, controlling for hypertension, coronary artery disease and diastolic function.

From an initial group of 2,042 residents of Olmsted County in US, 116 study participants with diabetes were matched 1:2 for age, hypertension, sex, coronary artery disease and diastolic dysfunction to 232 participants without diabetes.

Over the 10-year follow-up period, 21 per cent of participants with diabetes developed heart failure, independent of other causes. In comparison, only 12 per cent of patients without diabetes developed heart failure. Cardiac death, heart attack and stroke were not statistically different in the study between the two groups.

The study shows that diabetes is an independent risk factor for the development of heart failure in the community dwelling population. Furthermore, the outcome data support the concept of a diabetic cardiomyopathy.

Diabetes
Heart problems are a common development for people with diabetes and now researchers have found that diabetes is an independent risk factor for the development of heart failure in the community dwelling population. Pixabay

This research extends previous findings and demonstrates that even without a known cardiac structural abnormality and with a normal ejection fraction, diabetic patients are still at increased risk of developing heart failure as compared to their nondiabetic counterparts.

“The key takeaway is that diabetes mellitus alone is an independent risk factor for the development of heart failure,” said study senior author Horng Chen from Mayo Clinic in the US.

ALSO READ: Samsung Ships Approx 6.7 Million Galaxy 5G Smartphones Globally

“Our hope is that this study provides a strong foundation for further investigations into diabetes and heart failure. There is still much to learn and study in terms of this association and how to best diagnose and treat this condition,” Chen added. (IANS)

Next Story

Drugs That Treat Arthritis in Dogs Can Kill Cancer Cells: Study

Drug for arthritis in dogs can fight cancer in people

0
Cancer Cells
Drugs for diabetes, inflammation, alcoholism and even for treating arthritis in dogs can also kill cancer cells. Pixabay

Drugs for diabetes, inflammation, alcoholism — and even for treating arthritis in dogs — can also kill cancer cells in the lab, according to a new health news and study.

The researchers systematically analysed thousands of already developed drug compounds and found nearly 50 that have previously unrecognised anti-cancer activity.

The findings, which also revealed novel drug mechanisms and targets, suggest a possible way to accelerate the development of new cancer drugs or repurpose existing drugs to treat cancer.

“We thought we’d be lucky if we found even a single compound with anti-cancer properties, but we were surprised to find so many,” said study researcher Todd Golub from Harvard University in the US.

Cancer Cells
Most of the non-oncology drugs that killed cancer cells in the study did so by interacting with a previously unrecognized molecular target. (Representational Image). Pixabay

The study, published in the journal Nature Cancer, yet to employ the Broad’s Drug Repurposing Hub, a collection that currently comprises more than 6,000 existing drugs and compounds that are either FDA-approved or have been proven safe in clinical trials (at the time of the study, the Hub contained 4,518 drugs).

Historically, scientists have stumbled upon new uses for a few existing medicines, such as the discovery of aspirin’s cardiovascular benefits.

“We created the repurposing hub to enable researchers to make these kinds of serendipitous discoveries in a more deliberate way,” said study first author Steven Corsello, from Dana-Farber Cancer Institute and founder of the Drug Repurposing Hub.

The researchers tested all the compounds in the Drug Repurposing Hub on 578 human cancer cell lines from the Broad’s Cancer Cell Line Encyclopedia (CCLE).

Using a molecular barcoding method known as PRISM, which was developed in the Golub lab, the researchers tagged each cell line with a DNA barcode, allowing them to pool several cell lines together in each dish and more quickly conduct a larger experiment.

The team then exposed each pool of barcoded cells to a single compound from the repurposing library, and measured the survival rate of the cancer cells.

They found nearly 50 non-cancer drugs — including those initially developed to lower cholesterol or reduce inflammation — that killed some cancer cells while leaving others alone.

Some of the compounds killed cancer cells in unexpected ways.

“Most existing cancer drugs work by blocking proteins, but we’re finding that compounds can act through other mechanisms,” said Corsello.

Cancer Cells
The researchers tested all the compounds in the Drug Repurposing Hub on 578 human cancer cells lines from the Broad’s Cancer Cell Line Encyclopedia. (Representational Image). Pixabay

Some of the four-dozen drugs researchers identified appear to act not by inhibiting a protein but by activating a protein or stabilising a protein-protein interaction.

For example, the team found that nearly a dozen non-oncology drugs killed cancer cells that express a protein called PDE3A by stabilising the interaction between PDE3A and another protein called SLFN12 — a previously unknown mechanism for some of these drugs.

These unexpected drug mechanisms were easier to find using the study’s cell-based approach, which measures cell survival, than through traditional non-cell-based high-throughput screening methods, Corsello said.

Also Read- Mothers Find Gaps in Accessibility of Breastfeeding Resources at Work: Research

Most of the non-oncology drugs that killed cancer cells in the study did so by interacting with a previously unrecognized molecular target.

For example, the anti-inflammatory drug tepoxalin, originally developed for use in people but approved for treating osteoarthritis in dogs, killed cancer cells by hitting an unknown target in cells that overexpress the protein MDR1, which commonly drives resistance to chemotherapy drugs. (IANS)